UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 3 von 738
Datensatz exportieren als...
BibTeX
Efficacy and safety of bevacizumab in recurrent sex cord‐stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group
Cancer, 2014-02, Vol.120 (3), p.344-351
Brown, Jubilee
Brady, William E.
Schink, Julian
Le, Linda
Leitao, Mario
Yamada, S. Diane
Geest, Koen
Gershenson, David M.
2014
Details
Autor(en) / Beteiligte
Brown, Jubilee
Brady, William E.
Schink, Julian
Le, Linda
Leitao, Mario
Yamada, S. Diane
Geest, Koen
Gershenson, David M.
Titel
Efficacy and safety of bevacizumab in recurrent sex cord‐stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group
Ist Teil von
Cancer, 2014-02, Vol.120 (3), p.344-351
Ort / Verlag
Hoboken, NJ: Wiley-Blackwell
Erscheinungsjahr
2014
Link zum Volltext
Quelle
Free E-Journal (出版社公開部分のみ)
Beschreibungen/Notizen
BACKGROUND The Gynecologic Oncology Group conducted this phase 2 trial to estimate the antitumor activity of bevacizumab and to determine the nature and degree of toxicity in patients with recurrent sex cord‐stromal tumors of the ovary. METHODS A prospective, multi‐institutional cooperative group trial was performed in women with recurrent, measurable ovarian stromal tumors. Patients were allowed to have unlimited prior therapy, excluding bevacizumab. Bevacizumab 15 mg/kg was administered intravenously on day 1 of every 21‐day cycle until patients developed disease progression or adverse effects that prohibited further treatment. The primary endpoint was the response rate (RR). Inhibin A and B levels were measured before each cycle, and the values were examined in relation to response and progression. RESULTS Thirty‐six patients were enrolled, and all were eligible and evaluable. Patients received a median of 9 cycles of treatment (range, 2‐37 cycles). Six patients (16.7%) had partial responses (90% confidence interval, 7.5%‐30.3%), 28 patients (77.8%) had stable disease, and 2 patients (5.6%) had progressive disease. This met the criterion for declaring the regimen active. The median progression‐free survival was 9.3 months, and the median overall survival was not reached in during reporting period. Two grade 4 toxicities occurred, including hypertension and proteinuria; and the most common grade 3 toxicities were hypertension (n = 5) and pain (n = 5). Inhibin A and B values were lower in patients who responded to treatment. CONCLUSIONS Bevacizumab has activity in the treatment of recurrent sex cord‐stromal tumors of the ovary, and its toxicity is acceptable. Further investigation is warranted. Cancer 2014;120:344–351. © 2013 American Cancer Society. Bevacizumab has activity in recurrent stromal ovarian tumors and appears to have an acceptable safety profile. Inhibin A and B appear to be associated with response to therapy.
Sprache
Englisch
Identifikatoren
ISSN: 0008-543X
eISSN: 1097-0142
DOI: 10.1002/cncr.28421
Titel-ID: cdi_crossref_primary_10_1002_cncr_28421
Format
–
Schlagworte
Adult
,
Aged
,
Angiogenesis Inhibitors - therapeutic use
,
Antibodies, Monoclonal, Humanized - adverse effects
,
Antibodies, Monoclonal, Humanized - therapeutic use
,
Bevacizumab
,
Biological and medical sciences
,
Female
,
Gynecologic Oncology Group
,
Humans
,
Inhibins - blood
,
Medical sciences
,
Middle Aged
,
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
,
Neoplasm Recurrence, Local - drug therapy
,
Ovarian Neoplasms - blood
,
Ovarian Neoplasms - drug therapy
,
Ovarian Neoplasms - mortality
,
Prospective Studies
,
Sex Cord-Gonadal Stromal Tumors - blood
,
Sex Cord-Gonadal Stromal Tumors - drug therapy
,
Sex Cord-Gonadal Stromal Tumors - mortality
,
stromal ovarian tumors
,
survival
,
Tumors
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX